Survival advantage of exemestane (EXE, Aromasin®) over megestrol acetate (MA) in postmenopausal women with advanced breast cancer (ABC) refractory to tamoxifen (TAM): results of a phase III randomized double-blind study
- 30 September 1999
- journal article
- abstracts
- Published by Elsevier in European Journal Of Cancer
- Vol. 35, S84
- https://doi.org/10.1016/s0959-8049(99)80705-9
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: